There certainly is an element of risk included. Yet, personally I deem it pretty small as the main idea of sozinibercept - that‘s blocking the VEGF-C pathway - holds true for all anti-VEGF-A agents - be it Lucentis, Eylea, Avastin, Beovu or Fabysmo - as they all lead to an unintended upregulation of VEGF-C as the main escape pathway of progressing angionesis.
Ann: Security Class Reinstatement to Quotation- OPTOB, page-21
-
- There are more pages in this discussion • 178 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
0.005(0.93%) |
Mkt cap ! $670.9M | |||
| Open | High | Low | Value | Volume |
| 54.5¢ | 56.0¢ | 53.8¢ | $817.0K | 1.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 619 | 54.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.0¢ | 27532 | 3 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |